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httpPercutaneous thoracic endovascular aortic repair is
not contraindicated in obese patients
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Thomas M. Beaver, MD, MS,b Tomas D. Martin, MD,b Thomas S. Huber, MD, PhD,a and
Robert J. Feezor, MD,a Gainesville, Fla
Objective: There are limited data describing the preclose technique with the Perclose ProGlide device (Abbott Vascular,
Redwood City, Calif) in percutaneous thoracic endovascular aortic repair (P-TEVAR), particularly in obese patients, in
whom use of this technique is thought to be relatively contraindicated. The purpose of this analysis was to describe our
experience with P-TEVAR and to compare outcomes in patients with or without obesity.
Methods: All TEVAR procedures at a single institution from 2005 to 2011 were reviewed, and P-TEVAR patients were
stratiﬁed by body mass index (obesity $ 30 kg/m2). Preoperative computed tomography scans were analyzed for access
vessel depth, calciﬁcation, and morphology. Technical success was deﬁned as the ability to achieve hemostasis and to
maintain limb perfusion without the need for common femoral artery exposure or obligate surgical repair of the vessel
within a 30-day postoperative period. Generalized estimating equations and stepwise logistic regression were used to
develop prediction models of preclose failure.
Results: The review identiﬁed 536 patients, in whom 355 (66%) P-TEVAR procedures were completed (366 arteries;
n [ 40 [11%] bilateral). Compared with nonobese patients (n [ 264), obese patients (n [ 91) were typically younger
(59 6 16 years vs 66 6 16 years; P [ .0004) and more likely to have renal insufﬁciency (28% vs 17%; P [ .05) or
diabetes mellitus (19% vs 9%; P [ .02). The number of Perclose deployments was similar between groups (P [ NS).
Mean sheath size (25.4F vs 25.0F; P [ .04), access vessel inner diameters (8.5 6 1.9 mm vs 7.9 6 2.0 mm; P [ .02),
and vessel depth (50 6 20 mm vs 30 6 13 mm; P < .0001) were greater in obese patients. Adjunctive iliac stents were
used in 7% of cases (10 [11%] in obese patients vs 16 [6%] in nonobese patients; P [ .2). Overall technical success was
92% (92% for nonobese patients vs 93% for obese patients; P [ .7). Three patients required subsequent operations for
access complications, two obese patients (2%) and one nonobese patient (0.4%) (P [ .3). Independent predictors of
failure were adjunctive iliac stent (odds ratio [OR], 9.5; 95% conﬁdence interval [CI], 3.3-27.8; P < .0001), more than two
Perclose devices (OR, 7.0; 95% CI, 2.3-21; P [ .0005), and smaller access vessel diameter to sheath size ratio (OR
multiplies by 1.1 for each .01 decrease in ratio; 95% CI, 1.02-1.2; P [ .007) (area under the receiver operating
characteristic curve [ .75).
Conclusions: Obesity is not a contraindication to P-TEVAR. P-TEVAR can be performed safely, despite the need for
larger diameter sheaths. However, patients predicted to need adjunctive stenting or possessing smaller access vessel
diameter to sheath size ratios are at highest risk of preclose failure with the Perclose ProGlide device, and selective use of
this technique is recommended. (J Vasc Surg 2014;60:921-8.)Thoracic endovascular aneurysm repair (TEVAR) is
increasingly performed for a variety of thoracic aortic dis-
eases.1-3 Thoracic endografts tend to be larger in diameterthe Division of Vascular Surgery and Endovascular Therapya and
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Consequently, TEVAR procedures are often performed
by delivery of the endograft through open femoral expo-
sure or creation of an aortic/iliac conduit in 20% to 30%
of cases.4,5 Because of the success of the preclose technique
for aortic endograft placement,6,7 our practice has evolved
to implement this access strategy in the majority of TEVAR
patients (P-TEVAR), despite the need for larger sheath
sizes.
In addition to shorter operative times,7 potential ad-
vantages of percutaneous access include reduced discom-
fort, earlier ambulation, and lower rate of wound
complications.8,9 Wound complications with open femoral
exposure in endovascular aortic repair (EVAR) have been
reported in 3% to 5% of patients, despite efforts to reduce
this risk by making limited transverse or oblique inci-
sions.10 Obesity is a known risk factor for groin wound
morbidity,10,11 and this patient population potentially
stands to beneﬁt the most from percutaneous access for
endovascular aortic procedures. However, in initial reports921
Fig 1. Method of femoral access vessel assessment. The common femoral artery (CFA) was located at the midefemoral
head, and a measurement from the skin to the anterior vessel wall was obtained to determine access vessel depth (A).
The left-right (B) and anterior-posterior (C) inner vessel diameters as well as plaque morphology and calcium score
were obtained for each vessel accessed with a sheath that was 20F outer diameter or larger.
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tive contraindication because of concerns about access
vessel depth and suture capture.7,12
Currently, there are limited data analyzing P-TEVAR,
and no publications speciﬁcally examine the impact of
obesity on procedural safety and success. The purpose of
this analysis was to describe our experience with P-TEVAR
and to compare outcomes in obese and nonobese patients.
METHODS
Approval for this study was obtained from the Univer-
sity of Florida College of Medicine Institutional Review
Board. A waiver of informed consent was granted because
all collected data pre-existed in medical records and no
study-related interventions or subject contact occurred.
Therefore, the rights and welfare of these subjects was
not adversely affected.
Database and subjects. All patients undergoing
TEVAR for any indication at the University of Florida
between 2005 and 2011 were prospectively entered into
an endovascular database. This database was queried for
demographics, comorbidities, indications, andpostoperative
complications. Conﬁrmation of patient- and procedure-
speciﬁc outcomes was veriﬁed with retrospective review
of the electronic medical record. Comorbidities and
procedure-related outcomes were deﬁned and graded by
Society for Vascular Surgery reporting guidelines.13 Pa-
tients undergoing percutaneous access and closure of a
common femoral artery (CFA) who received thoracic
endograft delivery were identiﬁed and further reviewed.
Subjects undergoing femoral exposure or open conduit
placement for device insertion were excluded. Preoperative
computed tomography (CT) angiograms were examined
to determine anatomic and morphologic data that were
not routinely entered in the database, including access
vessel depth, degree of femoral plaque burden, and
calciﬁcation.
Deﬁnitions. Patients were dichotomized as obese or
nonobese, and outcomes were further analyzed. Obesitywas deﬁned as a body mass index (BMI) $30 kg/m2
(World Health Organization deﬁnition: www.who.int/
mediacentre/factsheets).14 Technical success of the pre-
close technique during TEVAR was deﬁned as the ability to
achieve hemostasis and to maintain limb perfusion without
the need for CFA exposure or obligate surgical repair of the
vessel for 30 days postoperatively. Any access-related
complications identiﬁed in the electronic medical record
or on postoperative CT review were also considered fail-
ures. These events were tabulated even if they were
conservatively managed. Complications that were catego-
rized as a preclose technical failure included development
of lower extremity emboli, surgical site infection (deep or
superﬁcial requiring antibiotics or surgical débridement),
de novo access vessel lesions such as hematoma (which was
clinically diagnosed and treated either conservatively or
with surgical evacuation), ﬂow-limiting dissections, clini-
cally signiﬁcant stenosis (eg, new-onset claudication/limb
ischemia, $50% cross-sectional diameter reduction, or
vessel occlusion), pseudoaneurysms, arteriovenous ﬁstulas,
or documented Perclose device malfunction requiring
arterial repair.
Access vessel evaluation. CFA depth and cross-
sectional diameter were measured from a predeﬁned
anatomic reference point. The reference point was chosen
in the mid-femoral head and measured in a straight line
from the anterior vessel wall to the skin surface immediately
overlying the artery. This was thought to be the most
consistent anatomic marker for analysis of vessel depth and
morphology, and it is typically above the CFA bifurcation
(Fig 1). Per our protocol, the caudal extent of all CT scans
extended below the femoral head, and the entire femoral
bifurcation was visualized for any anatomic variation for
each patient. If a patient’s femoral artery bifurcation was
located cranial relative to the femoral neck, the vessel depth
was measured at the location of the bifurcation.
CFA calciﬁcation and morphology were scored on the
basis of presence or absence of atherosclerotic plaque from
the superﬁcial epigastric artery to the femoral bifurcation
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plaque or calcium involving $50% of luminal diameter;
3, anterior wall calciﬁcation; 4, circumferential calciﬁca-
tion). A similar scoring system has been previously
described in a report predicting vascular complications of
percutaneous aortic valve replacement.15 Two independent
observers (J.Z., S.S.) reviewed postoperative imaging
and scored femoral access anatomy and morphology.
Observed agreement between the reviewers was 96% with
a k of 0.92 (95% conﬁdence interval [CI], 0.86-1.00).
Clinical practice. TEVAR case planning in all patients
was completed on a three-dimensional workstation
(Aquarius; TeraRecon, Inc, San Mateo, Calif), and access
vessel diameter, tortuosity, and calciﬁcation were routinely
evaluated. The surgeon’s discretion determined eligibility
of patients for P-TEVAR, and no standard criteria were
used to select patients during the study interval. All
TEVAR patients routinely underwent pulse examination
preoperatively and postoperatively. In addition, Doppler
insonation was commonly used to evaluate pedal signals at
the beginning and end of each case and throughout the
patient’s hospitalization. Selective use of ankle-brachial
indices occurred in patients with pre-existing peripheral
arterial occlusive disease, but no standardized protocol was
in place during the study period. The need for adjunctive
interventions, such as conduits or iliac angioplasty and stent
placement, was left to the surgeon’s discretion. In general,
iliac diameters #7 mm and presence of signiﬁcant athero-
sclerotic disease often prompted selective iliac angioplasty
(6stent) or open or endovascular conduit use.
Preclose technique. An in-depth description of the
technical elements of percutaneous access in aortic
endograft repair has been described previously by our
group and others.7,9,12 Brieﬂy, in the majority of cases,
initial percutaneous access was achieved with a 21-gauge
micropuncture needle placed through the anterior CFA
wall with ﬂuoroscopic guidance16 or selective ultrasound
visualization,17 depending on the surgeon’s preference. A
0.018-inch introducer wire was passed through the access
needle, followed by Seldinger exchange for a 4F introducer
sheath (Cook Medical, Bloomington, Ind). Whereas some
surgeons in the group use bone landmarks at the time of
blood return from the micropuncture needle to determine
the puncture site, others perform hand injection digital
subtraction arteriography with a magniﬁed, ipsilateral
oblique view to verify successful CFA cannulation.
Next, thepreclose technique7was completedwith thePer-
closeProGlidedevice (AbbottVascular,RedwoodCity,Calif).
The ProGlide device is a suture-mediated access closure device
that is designed to provide closure of a 5F to 21F arteriotomy
by deploying two small nitinol needles through the entire
thickness of the anterior CFA wall, with two devices required
for >8F sheaths, per the instructions for use. These needles
are attached to a pretied, 3-0 Prolene suture. Within the in-
structions for use, the manufacturer explicitly states that the
ProGlide system is designed for closure of only common
femoral arteriotomy up to 21F with the preclose technique
and has not been tested in patients with signiﬁcant arterialcalciﬁcation, obesity, or need for larger sheath diameters
(http://www.abbottvascular.com/static/cms_workspace/
pdf/ifu/vessel_closure/eIFU_Perclose_ProGlide.pdf).
Our technique represents an “off-label use” as several
patients within this study had some or all of these attributes.
To complete the preclose technique, we deploy two Pro-
Glide sutures at the beginning of the procedure, offset by
10-degree rotation in a medial and lateral direction. The
pretied knot is tied down after procedure completion as pre-
viously described.7 The surgeon’s choice determined the
need to place additional sutures at case completion, depend-
ing on impression of hemostasis. Judgment of the need to
perform femoral exposure and repair because of preclose
failure was left to the operating surgeon’s discretion.
Statistical methods. A majority of patients were
determined to have one preclose site per TEVAR proce-
dure, and contralateral femoral access outcomes were not
included in the analysis (typical contralateral CFA sheath
diameters ¼ 6F) unless the contralateral sheath was >20F
outer diameter. In those cases in which the contralateral
sheath was >20F outer diameter and the preclose tech-
nique was used, those vessels were analyzed as a separate
vessel in the analysis.
Continuous variables were analyzed by Student t-test,
and categorical variables were compared with c2 or Fisher
exact test. Generalized estimating equations were used to
assess whether BMI (considered a continuous variable)
was a predictor of failure in accounting for covariates. Pre-
close failure was used as the outcome variable. The primary
predictor was BMI, and patients were treated as a repeated
factor to account for the double observations (bilateral
CFA access) for some cases. Manual backward stepwise
elimination was performed on the basis of P values and
model predictive power. Because the primary interest was
in BMI, BMI was retained as a covariate in all models
regardless of its estimated effect, and all interactions be-
tween BMI and the other covariates were also tested. All
data processing and statistical analysis were completed
with the R statistical software package (https://www.r-
project.org/). A P value < .05 was considered signiﬁcant.
RESULTS
Between March 2003 and May 2011, 536 TEVAR
patientswere identiﬁed, ofwhom355 (66%) had total percu-
taneous access by the preclose technique (Fig 2). There were
366 P-TEVAR arteries identiﬁed that were closed by
Perclose ProGlide devices, with a mean of 2.16 0.4 devices
used per artery. There were 270 men (76%), and the overall
mean (6standard deviation) BMI was 26.6 6 5.4. There
were 91 patients identiﬁed with a BMI $30 kg/m2, and
mean BMI in this cohort of patients was 34.86 3.8. Differ-
ences in demographics of nonobese and obese patients
are highlighted in Table I.Notably, obese patients were typi-
cally younger and more likely to be male and to have renal
insufﬁciency or diabetes mellitus. However, obese patients
less frequently had a history of coronary artery disease.
Details of the anatomic and procedure-speciﬁc vari-
ables are highlighted in Table II. The mean access vessel
Table I. Patient characteristics and comorbiditiesa
Nonobese
(n ¼ 264),
No. (%)
Obese (BMI > 30)
(n ¼ 91),
No. (%) P value
Feature
Mean age 6 SD, years 66 6 16 59 6 16 .0004
Female 71 (27) 15 (17) .06
Prior groin operation 13 (7) 2 (3) .2
Comorbidities
Hypertension 220 (86) 79 (87) .9
Dyslipidemia 105 (41) 31 (34) .3
Smoking 91 (36) 29 (32) .6
Coronary artery disease 67 (26) 14 (15) .04
COPD 50 (20) 11 (12) .1
Renal insufﬁciency 44 (17) 25 (28) .05
Arrhythmia 34 (13) 8 (9) .3
Diabetes mellitus 23 (9) 17 (19) .02
Cerebrovascular disease 28 (11) 6 (7) .3
Peripheral arterial disease 20 (8) 4 (4) .4
Congestive heart failure 15 (6) 4 (4) .8
BMI, Body mass index; COPD, chronic obstructive pulmonary disease; SD,
standard deviation.
aFisher exact test, t-test, or c2 test when appropriate.
Table II. Anatomic and procedure-speciﬁc variables
between nonobese and obese P-TEVAR patients
(mean 6 SD)a
Feature
Nonobese
(n ¼ 274)
Obese
(BMI $ 30)
(n ¼ 92) P value
Preclose vessel
Bilateral access 31 (11) 9 (10)
Left femoral artery 60 (22) 17 (18)
Right femoral artery 183 (67) 66 (72) .7
Procedural urgency
Elective 168 (61) 57 (62)
Urgent/emergent 106 (39) 35 (38) 1
Access vessel depth, mm 30 6 13 50 6 20 <.0001
Access vessel inner
diameter, mm
7.9 6 2.0 8.5 6 1.9 .02
Largest sheath diameter, F 25.0 6 1.5 25.4 6 1.4 .04
Maximum stent
diameter, mm
35.3 6 5.7 36.2 6 4.8 .2
No. of Perclose devices used 2.1 6 0.4 2.1 6 0.4 .3
Iliac stent use 16 (6) 10 (11) .2
BMI, Body mass index; P-TEVAR, percutaneous thoracic endovascular
aortic repair; SD, standard deviation.
Continuous data are presented as mean 6 SD and categorical data as
number (%).
aFisher exact test, Mann-Whitney test, or c2 test when appropriate.
Fig 2. Patient and access vessel selection for percutaneous thoracic
endovascular aortic repair (TEVAR). A total of 536 patients were
available at the time of analysis, with 365 arteries from 355 patients
accessed with a sheath that was $20F outer diameter. Of these,
336 were successfully closed percutaneously by the preclose tech-
nique, with 29 failures. When body mass index (BMI) $30 was
used as a deﬁnition of obesity, it was not associated with a higher
rate of failure (P ¼ NS vs nonobese patients).
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average depth of 50 6 20 mm compared with 30 6 13 mm
for nonobese patients (P < .0001; Fig 3, A). Mean sheath
diameter was slightly larger among obese patients (P ¼
.04), but average stent diameters were similar between
the two groups. Obese patients were more likely to have
larger inner femoral access vessel diameters compared
with nonobese patients (P ¼ .02; Fig 3, B). Pre-TEVAR
deployment adjunctive iliac stents were used in 7%
(n ¼ 27) of all cases (11% of obese patients vs 6% of non-
obese patients; P ¼ .2). More than two ProGlide devices
were used in 8.8% (n¼ 32) of cases. For the 294 (80%) pro-
cedures in which patients had adequate CT imaging for
femoral plaque and calcium scoring, there was no
difference in categorization of access vessel morphology
between obese and nonobese patients (P ¼ .3; Table III).
The overall preclose success rate was 92%: 91% for non-
obese patients and 93% for obese patients (P ¼ .7).
Twenty-nine patients had documented technical failure of
the preclose technique during their TEVAR procedure.
No perioperative deaths were identiﬁed that were directly
attributed to failed percutaneous access. No signiﬁcant dif-
ferences in BMI were noted between patients experiencing
successful or unsuccessful percutaneous CFA closure
(P ¼ .2). Additional details of the analyzed covariates for
technical success of P-TEVAR are depicted in Table IV.
The outcomes of the 29 patients with failed percutaneous
access are demonstrated in Fig 4. Notably, most of the fail-
ures (90%; n ¼ 26) were recognized and managed at the
time of the index TEVAR procedure. Three patients
underwent subsequent operations within 30 days of
P-TEVAR for access vessel complications related to the
site of the preclose study vessel, two obese patients andone nonobese patient (P ¼ .3). The nonobese patient
had a left iliofemoral occlusion with subsequent repair.
The two remaining patients underwent femoral pseudoa-
neurysm repair (one mycotic, one nonmycotic).
Predictors of TEVAR preclose failure. Seventy-two
percutaneously accessed arteries had inadequate CT imag-
ing data for femoral plaque scoring because of lack of intra-
venous contrast. This was secondary to the emergent
nature of the procedures as well as the retrospective
methods of the study (20% of total observations). As
Fig 3. Body mass index (BMI) and access vessel morphology trends. These scatter plots demonstrate that as expected,
the access vessel depth is greater as the patient’s BMI increases (A). Of note, the inner vessel diameter also tended to be
larger with increasing BMI (B).
Table III. Access vessel morphology score as a function
of the patient’s body habitusa
Femoral artery disease
Nonobese
(n ¼ 215), No. (%)
Obese (BMI > 30)
(n ¼ 79), No. (%)
No calcium 82 (38) 41 (52)
Posterior wall plaque 74 (34) 22 (28)
>50% of vessel
circumference plaque
5 (2) 0
Anterior wall calcium 38 (18) 11 (14)
Circumferential calcium 16 (7) 5 (6)
BMI, Body mass index.
aP ¼ .3 by Fisher exact test; imaging to review for access vessel scoring was
not available for 72 procedures, and rate of missingness did not differ
between obese and nonobese patients.
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tained for these patients and thus were not considered in
the multivariable models. However, access vessel diameter
and vessel depth were included. The ﬁnal multivariable
analysis data set included 365 observations (29 failures
and 336 successes) in 355 patients; of note, the success
rate of the analyzed cohort did not differ signiﬁcantly
from the cohort not analyzed (92% vs 96%; P ¼ .23).
Probability of preclose failure during TEVAR was
inversely correlated toBMI,which had signiﬁcant interaction
with sheathdiameter (eg,YBMIþ[ sheath sizef[ failure).
Speciﬁcally, amongpatientswith failed percutaneous access, a
negative correlation (r¼0.21) was detected (18 of 29 fail-
ure patients [62%] had a BMI thatwas below the averageBMI
for the entire study cohort, and their average sheath sizes
were greater than those of the entire study cohort). This
interaction seemed greatest in patients with a BMI <26
who had a sheath >24F used during their P-TEVAR proce-
dure (odds ratio [OR], 2.3; 95% CI, 1.03-5.3; P ¼ .04).Additional covariates that had linear relationships with failed
percutaneous access included age and sheath size. Older pa-
tient age and increasing sheath size were correlated with
higher probability of preclose failure (Fig 5).
In examining the impact of access vessel diameter
to sheath size ratio, probability of failure increased in a
linear fashion (access vessel diameter to sheath size ratio
Y f [ failure; median ratio in successful P-TEVAR, .32
[interquartile range, .27-.37] vs failed P-TEVAR, .29
[interquartile range, .24-.33]; P ¼ .02). The interaction
between BMI and access vessel diameter to sheath size
ratio is depicted in Fig 6.
The ﬁnal multivariable model predicted preclose failure
correctly for 74.8% of subjects, and on the basis of this
modeling, independent predictors of failure were adjunc-
tive iliac stent (OR, 9.5; 95% CI, 3.3-27.8; P < .0001),
more than two ProGlide devices (OR, 7.0; 95% CI,
2.3-21; P ¼ .0005), and smaller access vessel diameter to
sheath size ratio (OR multiplies by 1.1 for each .01
decrease in ratio; 95% CI, 1.02-1.2; P ¼ .007).
DISCUSSION
This study demonstrated that percutaneous closure of
the CFA during TEVAR can be completed safely with a
high degree of technical success, independent of the pa-
tient’s BMI. This report represents one of the largest expe-
riences with P-TEVAR published to date and is the ﬁrst to
demonstrate that obesity is not associated with failure of
the preclose technique. The predictors of preclose failure
were primarily related to iliofemoral access vessel quality,
speciﬁcally access vessel diameter, sheath size, and need
for adjunctive iliac stenting. Interestingly, contrary to other
reports of percutaneous closure of large femoral access dur-
ing EVAR, larger sheath diameters (>24F) were not
Table IV. Comparison of tested covariates for success or
failure of percutaneous thoracic endovascular aortic repair
(P-TEVAR)
Feature
Success
(n ¼ 336)
Failure
(n ¼ 29)
P
valuea
BMI 27.5 (5) 26.4 (4) .2
Gender
Female 78 (90) 9 (10) .3
Age 64 (16) 70 (13) .03
Race
White 244 (72) 23 (79) .3
Black 69 (21) 3 (11)
Other 23 (7) 2 (9)
Prior groin operation 14 (93) 1 (7) .9
Sheath size, F 25.1 6 1.5 25.6 6 1.3 .05
Number of Perclose devices
#2 311 (93) 21 (72) .0007
>2 24 (7) 8 (28)
Iliac stent used 18 (5) 8 (28) <.0001
Access vessel
Both 35 (10) 4 (14)
Right 232 (69) 17 (59)
Left 69 (21) 8 (28) .5
Access vessel diameter,
mm
8.1 6 2.0 7.5 6 1.5 .08
Access vessel depth, mm 35.5 6 17.8 36.1 6 15.5 .8
Femoral plaque/calcium
scoreb
1.1 6 1.3 1.6 6 1.3 .04
Comorbidity score 2.6 6 1.5 3.1 6 1.8 .09
Urgency
Elective 208 (92) 17 (8) .7
Urgent/emergent 128 (91) 12 (9)
Device category
Cook 144 (92) 12 (8) .9
Gore 164 (93) 13 (7)
Other 26 (90) 3 (10)
BMI, Body mass index; SD, standard deviation.
Continuous data are presented as mean 6 SD and categorical data as
number (%).
aP values are the results of generalized estimating equations logistic models
to account for repeated observations on some subjects.
bFemoral plaque/calcium score was not used in the ﬁnal model because of
20% rate of missingness.
Fig 4. Preclose failure management during thoracic endovascular
aortic repair (TEVAR). Preclose failure was deﬁned as the inability
to achieve hemostasis and to maintain limb perfusion without the
need for common femoral artery (CFA) exposure or obligate
surgical repair of the vessel within a 30-day postoperative period
(see Methods section for further details). Three hematomas were
documented clinically and conﬁrmed with duplex ultrasound and
managed expectantly (no transfusion or evacuation). All of these
hematomas resolved during postoperative follow-up. Of the other
26 failures, four required an iliofemoral bypass, 10 required an
endarterectomy and patch angioplasty, and 12 arteriotomies were
repaired primarily.
Fig 5. Probability of preclose failure during percutaneous thoracic
endovascular aortic repair (P-TEVAR). This graph demonstrates
some of the univariate associations with preclose failure during P-
TEVAR. Notably, factors such as age and sheath diameter were
linearly correlated with failure; however, body mass index (BMI)
had an inverse relationship (eg, YBMI f [failure rate). Of the
three demonstrated variables in this graph, only sheath diameter
independently predicted failure in multivariable analysis. The
optimal prediction model was obtained in accounting for the
interaction of sheath size and access vessel inner diameter.
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in patients with lower BMI (<26).
In the initial report from our institution that demon-
strated safety of percutaneous CFA access for delivery of
aortic endografts, 71 of the 183 patients underwent
TEVAR. Compared with infrarenal aortic devices, thoracic
devices are typically larger and therefore the access-related
complication rates are frequently higher, regardless of the
technique chosen to deliver the device.4,18,19 As such, there
is signiﬁcant selection bias in any such report, as was
evident in our initial series in which the preclose cohort
was compared with a contemporaneous series of 154 surgi-
cally exposed femoral arteries. Nevertheless, it was shown
that smaller sheath access (12F-14F) was statistically
more likely than large groin access (20F-24F) to achieve
successful closure percutaneously (99% vs 91.4%; P < .01).7
These results are consistent with other publications on
percutaneous EVAR20 and potentially could curb enthu-
siasm for P-TEVAR.As overall clinical practice evolved and device/sheath
technology has improved with respect to both luminal pro-
ﬁle reduction and hydrophilic materials, clinicians have
become collectively more aggressive in pursuing minimally
Fig 6. Interaction between access vessel diameter and sheath size.
This plot demonstrates the interaction between the femoral access
vessel diameter and sheath size ratio as a function of the patient’s
body mass index (BMI). A decreasing access vessel diameter to
sheath size ratio (eg, smaller vessel and larger sheaths) was an in-
dependent predictor of preclose failure during percutaneous
thoracic endovascular aortic repair (P-TEVAR).
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a reduction in the number of iliac conduits, once reported to
be required in 20% of TEVAR procedures.4 Totally percuta-
neous EVAR now constitutes an overwhelming majority
(>95%) of our practice. Nationally, however, it is likely
that clinicians still use routine open femoral exposure during
EVAR for a variety of reasons, including a paucity of litera-
ture for P-TEVAR, technical unfamiliarity with the preclose
technique, and potential ﬁnancial implications of percuta-
neous suture closure device use and inability to submit a
reimbursement code for femoral exposure.
Patient-related factors such as age, gender, femoral ar-
tery calciﬁcation, obesity, and scarred or reoperative groin
vessels have been reported to contribute to percutaneous
failures and in some studies are used as exclusion criteria
of percutaneous aortic repair.20,22,23 Of note, a relative
contraindication to the preclose technique with our initial
experience was patient obesity.7,12 The greater vessel depth
and increased interposed periarterial fat were thought to
confer a higher risk of suture noncapture for the preclose
technique. Indeed, this bias was recently corroborated by
Skagius et al,24 who documented that increased groin
subcutaneous fat was associated with primary failure of
P-TEVAR with the Prostar XL device (Abbott Vascular).
However, in the current study, our results demonstrate
that obesity was not associated with lower technical success
in performing percutaneous aortic repair. Interestingly,
lower BMI was correlated with decreased vessel depth
but also inner vessel diameter (Fig 3, B), which was more
frequently associated with P-TEVAR failure when larger
sheath sizes were employed during the procedures (Fig 5).
With regard to vessel morphology, the results of this
analysis are consistent with previous reports of the impactof CFA disease on success of totally percutaneous aortic
repair.23,25 Speciﬁcally, higher femoral plaque scores were
associated with failure in the univariate analysis. However,
increased CFA plaque/calcium burden did not fall out in
the multivariable model as an independent predictor, and
this was likely related to multiple factors including the
nonparametric distribution of the scores, the fact that 20%
of patients had inadequate imaging to accurately discern pla-
que morphology (Table III), and the selection bias for
which patients were thought to be candidates for P-TEVAR.
Metcalfe et al8 reported that the success rate of percu-
taneous aortic endovascular repair in 186 femoral arteries
was 95.2%. On univariate analysis, they found that vessel
depth, diameter, preoperative renal failure, and operator
experience predicted failure of the percutaneous technique.
Of note, operators were considered “experienced” when
they had successfully performed 20 such procedures. On
multivariable analysis, only operator experience predicted
failure. Although this report used a single Prostar XL de-
vice, the overall success rate and impact of vessel diameter
were remarkably similar to our report. We did not specif-
ically examine operator experience as all of the operators
in this study were considered higher volume endovascular
aortic surgeons (>20 procedures/year).
Our current clinical practice for totally percutaneous
aortic repair involves extensive preoperative planning with
centerline of ﬂow three-dimensional reconstruction. Access
vessel depth, diameter, tortuosity, and calciﬁcation are eval-
uated, and assessment is made about the feasibility of trans-
femoral delivery of the endoprosthesis. Endovascular iliac
conduits19 are used selectively even in conjunction with
percutaneous CFA access. Clinical scenarios in which we
typically do not attempt percutaneous aortic repair include
procedures using an aorto-uni-iliac endograft for which a
femorofemoral bypass is planned, extensive anterior CFA
calciﬁcation, and presence of a prosthetic graft in the
femoral artery. The implications of percutaneous failure
are generally benign, and a sheath can be inserted for he-
mostasis while femoral exposure is performed. Thus, we
are aggressive with attempting totally percutaneous repair,
even in situations in which we think it may fail.
There are several important limitations to this study that
are inherent to its single-center retrospective design. First, it
was not possible for us to retrospectively determine the exact
site of femoral artery access for our vessel analysis, and we
acknowledge that we may not have evaluated the pertinent
portion of the femoral artery. Further, we were unable to
determine whether and to what degree the overlying skin
and subcutaneous tissue were cranially displaced during access,
as is often done in obese patients, which would alter the depth
of the artery from the skin. We think that these limitations
were mitigated by use of a ﬁxed bone landmark in all patients.
In addition, no standardized protocol was in place
that designated when patients underwent open femoral
exposure or percutaneous access for TEVAR. Because of
patient numbers, extensive subgroup analysis of different
obesity strata was not possible, so it is conceivable that in
patients with greater extremes of obesity, outcomes with
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modeling was not feasible because of the limited number
of preclose failure events. Unfortunately, the impact of
femoral plaque/calcium score could not be analyzed in
multivariable analysis owing to missing data. Importantly,
no comparison to the outcomes of standard open femoral
exposure during TEVAR was presented, but we have re-
ported this type of comparative analysis previously in a
mixed population of EVAR and TEVAR patients.6,7 Also,
routine preoperative and serial postoperative ankle-
brachial pressure index measurements were not uniformly
obtained, which may have provided a more sensitive assess-
ment of any hemodynamic perturbations caused by percu-
taneous access. Longer follow-up is needed to determine if
there are any risks for development of CFA stenosis after
percutaneous aortic repair. Last, all P-TEVAR procedures
were performed by surgeons with extensive totally percuta-
neous aortic repair experience, so the impact of the oper-
ator learning curve could not be analyzed.
CONCLUSIONS
P-TEVAR appears to be safe, despite the need for
larger diameter sheaths during the procedure. Obesity is
not a contraindication for the preclose technique; however,
patients predicted to need adjunctive stenting or possessing
smaller access vessel to sheath diameter ratios are at highest
risk of failure, and selective use of this technique is
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